甲福明不影响局部晚期直肠癌患者的结局,这些患者接受了新辅助疗法和切除治疗
Swati Sonal1,2, Chloe Boudreau1, Hiroko Kunitake1,2
1Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
The American surgeon
|November 16, 2023
概括
在接受新辅助治疗和手术的局部晚期直肠癌 (LARC) 患者中,甲福明的使用没有影响长期存活率. 建议对更大的队列进行进一步的研究,以证实这些关于癌症结局的发现.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 新出现的证据表明,甲可能提供癌症保护.
- 关于甲福明在局部晚期直肠癌 (LARC) 中的作用的数据仍然没有确定性.
- 这项研究调查了甲福明对接受新辅助疗法和切除术的LARC患者的影响.
研究的目的:
- 评估甲胺对LARC患者长期生存的影响.
- 评估甲福明使用者与非使用者的整体存活率 (OS) 和无疾病存活率 (DFS).
- 在LARC中分析甲福明对生存结果的预测价值.
主要方法:
- 对324名非转移性LARC患者 (2004-2018) 的回顾性审查.
- 27名甲福明使用者和297名非使用者之间的比较.
- 考克斯回归分析控制临床和病理变量.
主要成果:
- 甲胺使用者年龄较大,BMI和ASA得分较高,并且更多的30天再入院.
- 群体之间在OS (P=.18) 或DFS (P=.33) 中没有显著差异.
- 在考克斯回归分析中,甲胺摄入量没有预测OS或DFS.
结论:
- 在接受新辅助治疗和手术治疗的LARC患者中,甲福明似乎不会影响长期存活率.
- 需要进行更大规模的研究来验证这些发现.
- 甲胺在LARC治疗中的作用需要进一步研究.
更多相关视频
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.7K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
294
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
